AngioDynamics (NASDAQ:ANGO) Reaches New 12-Month High – Still a Buy?

AngioDynamics, Inc. (NASDAQ:ANGO)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $16.25 and last traded at $16.2160, with a volume of 12218 shares traded. The stock had previously closed at $15.82.

Analyst Ratings Changes

ANGO has been the subject of several analyst reports. Zacks Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Canaccord Genuity Group upped their target price on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, HC Wainwright lifted their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, AngioDynamics presently has a consensus rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Price Performance

The firm has a fifty day simple moving average of $13.73 and a two-hundred day simple moving average of $11.95. The firm has a market capitalization of $668.76 million, a P/E ratio of -18.59 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The firm had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, research analysts anticipate that AngioDynamics, Inc. will post -0.25 EPS for the current year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

Large investors have recently modified their holdings of the business. Farther Finance Advisors LLC boosted its holdings in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 1,199 shares during the period. Kemnay Advisory Services Inc. bought a new stake in AngioDynamics during the 4th quarter valued at $27,000. State of Wyoming bought a new stake in AngioDynamics during the 2nd quarter valued at $31,000. Legal & General Group Plc purchased a new stake in shares of AngioDynamics during the second quarter worth $45,000. Finally, Russell Investments Group Ltd. lifted its position in shares of AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.